Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study

J Acquir Immune Defic Syndr. 2005 Mar 1;38(3):320-8.

Abstract

Objective: Identify the determinants and consequences of interrupting and discontinuing highly active antiretroviral therapy (HAART) among a population-based cohort of HIV-infected men.

Methods: Longitudinal analyses were applied to 2916 person-visit pairs (589 men) of continuous HAART use, 243 person-visit pairs (154 men) during which HAART was interrupted, and 151 person-visit pairs (130 men) in which HAART was discontinued by the second visit. HIV RNA increase was defined as > or =1 log10 copies/mL across the visit pairs.

Result: : Younger age, black race, geographic location, higher HIV RNA level, depression, shorter time on HAART, lower medication adherence, and not taking a lamivudine-containing regimen predicted interrupting HAART use. Younger age, higher HIV RNA level, depression, and taking an abacavir- or lopinavir-containing regimen predicted discontinuing HAART. Among men with < or =1000 HIV RNA copies/mL, approximately 5% of those who interrupted HAART for < or =7 days and those who continued HAART had an HIV RNA increase. Men with longer interruptions and HAART discontinuers had significantly higher rates of HIV RNA increases (35.7% and 70.5%, respectively). Discontinuation and long interruptions resulted in lower CD4 cell counts.

Conclusions: Host characteristics play a role in short interruptions, whereas longer interruptions may be clinically indicated. These longer stoppages had further virologic and immunologic consequences, however.

Publication types

  • Multicenter Study
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Age Factors
  • Antiretroviral Therapy, Highly Active*
  • CD4 Lymphocyte Count
  • Cohort Studies
  • Depression
  • Dideoxynucleosides / therapeutic use
  • Ethnicity
  • HIV / genetics
  • HIV / growth & development
  • HIV Infections / drug therapy*
  • Humans
  • Logistic Models
  • Lopinavir
  • Male
  • Middle Aged
  • Pyrimidinones / therapeutic use
  • RNA, Viral / blood
  • Risk Factors
  • Treatment Refusal

Substances

  • Dideoxynucleosides
  • Pyrimidinones
  • RNA, Viral
  • Lopinavir
  • abacavir